PT - JOURNAL ARTICLE AU - Arran Hamlet AU - Dereje Dengela AU - J. Eric Tongren AU - Fitsum G Tadesse AU - Teun Bousema AU - Marianne Sinka AU - Aklilu Seyoum AU - Seth R. Irish AU - Jennifer S. Armistead AU - Thomas Churcher TI - The potential impact of <em>Anopheles stephensi</em> establishment on the transmission of <em>Plasmodium falciparum</em> in Ethiopia and prospective control measures AID - 10.1101/2021.08.19.21262272 DP - 2022 Jan 01 TA - medRxiv PG - 2021.08.19.21262272 4099 - http://medrxiv.org/content/early/2022/03/14/2021.08.19.21262272.short 4100 - http://medrxiv.org/content/early/2022/03/14/2021.08.19.21262272.full AB - Background Sub-Saharan Africa has seen substantial reductions in cases and deaths due to malaria over the past two decades. While this reduction is primarily due to an increasing expansion of interventions, urbanisation has played its part as urban areas typically experience substantially less malaria transmission than rural areas. However, this may be partially lost with the invasion and establishment of Anopheles stephensi. An. stephensi, the primary urban malaria vector in Asia, was first detected in Africa during 2012 in Djibouti and was subsequently identified in Ethiopia in 2016, and later in Sudan and Somalia. In Djibouti, malaria cases have increased 30-fold from 2012 to 2019 though the impact in the wider region remains unclear.Methods Here we have adapted an existing model of mechanistic malaria transmission to estimate the increase in vector density required to explain the trends in malaria cases seen in Djibouti. To account for the observed plasticity in An. stephensi behaviour, and the unknowns of how it will establish in a novel environment, we sample behavioural parameters in order to account for a wide range of uncertainty. This quantification is then applied to Ethiopia, considering temperature-dependent extrinsic incubation periods, pre-existing vector-control interventions and Plasmodium falciparum prevalence in order to assess the potential impact of An. stephensi establishment on P. falciparum transmission. Following this, we estimate the potential impact of scaling up ITN (insecticide treated nets)/IRS (indoor residual spraying) and implementing piperonyl butoxide (PBO) ITNs and larval source management,, as well as their economic costs.Results We estimate that annual P. falciparum malaria cases could increase by 50% (95% CI 14-90) if no additional interventions are implemented. The implementation of sufficient control measures to reduce malaria transmission to pre-stephensi levels will cost hundreds of millions of USD.Conclusions Substantial heterogeneity across the country is predicted and large increases in vector control interventions could be needed to prevent a major public health emergency.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding support from the United States Presidents Malaria Initiative and the MRC Centre for Global Infectious Disease Analysis (reference MR/R015600/1). The MRC Centre for Global Infectious Disease Analysis is jointly funded by the UK Medical Research Council (MRC) and the UK Foreign, Commonwealth &amp; Development Office (FCDO), under the MRC/FCDO Concordat agreement and is also part of the EDCTP2 programme supported by the European Union; and acknowledges funding by Community Jameel. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the U.S. Presidents Malaria Initiative.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and code required to run the analyses are found at https://github.com/arranhamlet/stephensi_ETH_publication https://github.com/arranhamlet/stephensi_ETH_publication ITNInsecticide treated netsIRSIndoor residual sprayingPBOpiperonyl butoxideEIPExtrinsic Incubation PeriodLHSLatin Hypercube SamplingMAPMalaria Atlas ProjectWMRWorld Malaria ReportLSMLarval Source ManagementPMIPresidents Malaria InitiativeWHOWorld Health Organization